Novavax posts positive preclinical results for flu/COVID-19 vaccine

By The Science Advisory Board staff writers

May 10, 2021 -- Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.

The vaccine is a combination of NanoFlu and the company's COVID-19 candidate NVX-CoV2373; results from the preclinical animal trial were published May 5 on bioRxiv. The study found that the combination elicited strong responses against both influenza A and B and protected against the SARS-CoV-2 virus, according to the firm. It expects to begin clinical studies of the combination by the end of this year.

NVX-CoV2373 is also being evaluated in two phase II trials, one in South Africa and one in the U.S. and Australia, as well as two phase III trials, one in the U.K. and another in the U.S. and Mexico, according to Novavax.

Novavax COVID vaccine effective vs. B.1.351 variant, inks deal with Gavi
Novavax announced results of a phase IIB trial of its COVID-19 candidate vaccine (NVX-CoV2373) published May 5 in the New England Journal of Medicine...
Novavax expands COVID-19 vaccine trial to include adolescents
Novavax has started a pediatric expansion of its phase III clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against...
Novavax COVID-19 vaccine to be included in combo vaccine study
Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The...
GSK to provide services for Novavax's COVID-19 vaccine in the U.K.
GlaxoSmithKline (GSK) has signed an agreement in principle to support manufacturing of up to 60 million doses of Novavax's NVX-CoV2373 COVID-19 vaccine...
Novavax confirms efficacy against U.K., South African SARS-CoV-2 strains
Novavax's SARS-CoV-2 vaccine candidate NVX-CoV2373 has a 96.4% efficacy against mild, moderate, and severe disease caused by the original COVID-19 strain,...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter